REFERENCES
- O′Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumour Growth. Cell 1997, Jan 24; 88(2)277–285
- ten Hagen T.L.M., Eggermont A.M.M., Lejeune F.J. TNF is Here to Stay–-Revisited. Trends Immunol. 2001, Mar.; 22(3)127–129
- Eggermont A.M.M., ten Hagen T.L.M. Isolated Limb Perfusion for Extremity Soft-Tissue Sarcomas, In-Transit Metastases, and Other Unresectable Tumors: Credits, Debits, and Future Perspectives. Curr. Oncol. Rep. 2001, Jul.; 3(4)359–367
- Lienard D., Ewalenko P., Delmotte J.J., Renard N., Lejeune F.J. High-Dose Recombinant Tumour Necrosis Factor Alpha in Combination with Interferon Gamma and Melphalan in Isolation Perfusion of the Limbs for Melanoma and Sarcoma. J. Clin. Oncol. 1992, Jan.; 10(1)52–60
- Eggermont A.M.M., Schraffordt Koops H., Klausner J.M., Kroon B.B., Schlag P.M., Lienard D., van Geel A.N., Hoekstra H.J., Meller I., Nieweg O.E., Kettelhack C., Ben-Ari G., Pector J.C., Lejeune F.J. Isolated Limb Perfusion with Tumour Necrosis Factor and Melphalan for Extremity Sarcomas. The Cumulative Multicenter European Experience. Ann. Surg. 1996, Dec.; 224(6)756–764, discussion 764–765
- de Wilt J.H.W., Manusama E.R., van Tiel S.T., van Ijken M.G.A., ten Hagen T.L.M., Eggermont A.M.M. Prerequisites for Effective Isolated Limb Perfusion using Tumour Necrosis Factor Alpha and Melphalan in Rats. Br. J. Cancer 1999, Apr.; 80(1–2)161–166
- de Wilt J.H.W., ten Hagen T.L.M., de Boeck G., van Tiel S.T., de Bruijn E.A., Eggermont A.M.M. Tumour Necrosis Factor Alpha Increases Melphalan Concentration in Tumour Tissue after Isolated Limb Perfusion. Br. J. Cancer 2000, Mar.; 82(5)1000–1003
- van der Veen A.H., de Wilt J.H.W., Eggermont A.M.M., van Tiel S.T., Seynhaeve A.L.B., ten Hagen T.L.M. TNF-alpha Augments Intratumoural Concentrations of Doxorubicin in TNF-alpha-based Isolated Limb Perfusion in Rat Sarcoma Models and Enhances Anti-Tumour Effects. Br. J. Cancer 2000, Feb.; 82(4)973–980
- Kristensen C.A., Nozue M., Boucher Y., Jain R.K. Reduction of Interstitial Fluid Pressure after TNF-alpha Treatment of Three Human Melanoma Xenografts. Br. J. Cancer 1996, Aug.; 74(4)533–536
- ten Hagen T.L.M., Van Der Veen A.H., Nooijen P.T.G.A., Van Tiel S.T., Seynhaeve A.L.B., Eggermont A.M.M. Low-dose Tumour Necrosis Factor-alpha Augments Antitumor Activity of Stealth Liposomal Doxorubicin (DOXIL) in Soft Tissue Sarcoma-Bearing Rats. Int. J. Cancer 2000, Sep. 15; 87(6)829–837
- van der Veen A.H., Eggermont A.M.M., Seynhaeve A.L.B., van Tiel S.T., ten Hagen T.L.M. Biodistribution and Tumour Localization of Stealth Liposomal Tumour Necrosis Factor-alpha in Soft Tissue Sarcoma Bearing Rats. Int. J. Cancer 1998, Sep. 11; 77(6)901–906
- ten Hagen T.L.M., Seynhaeve A.L.B., van Tiel S.T., Ruiter D.J., Eggermont A.M.M. Pegylated Liposomal Tumour Necrosis Factor-alpha Results in Reduced Toxicity and Synergistic Antitumor Activity after Systemic Administration in Combination with Liposomal Doxorubicin (Doxil) in Soft Tissue Sarcoma-Bearing Rats. Int. J. Cancer 2002, Jan. 1; 97(1)115–120
- Gridley D.S., Li J., Kajioka E.H., Andres M.L., Moyers M.F., Slater J.M. Combination of pGL1-TNF-alpha Gene and Radiation (Proton and Gamma-Ray) Therapy Against Brain Tumour. Anticancer Res. 2000, Nov-Dec.; 20(6B)4195–4203
- Kim D.W., Andres M.L., Li J., Kajioka E.H., Miller G.M., Seynhaeve A.L.B., ten Hagen T.L.M., Gridley D.S. Liposome-encapsulated Tumour Necrosis Factor-alpha Enhances the Effects of Radiation against Human Colon Tumour Xenografts. J. Interferon Cytokine Res. 2001, Nov.; 21(11)885–897